4KASHIF M,QURESHI A, ADIL SN, et al. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura[J]. J Pak Med Assoc, 2010, 60 (1):64-65.
5YAMASHITA M, KATAKURA Y, SHIRAHATA S, et al. Recent advances in the generation of human monoclonal antibody[J].Cytotechnology,2007,55:55-60.
7YAMAZAKI S, SUZUKI N, SAITO T, et al. A rapid and ef- ficient strategy to generate allele-specific anti-HLA monoclonal antibodies [J]. J Immunol Methods, 2009, 343 (1):56-60.
8MERRILL Jr, NEUWELT CM, WALLACE DJ, et al. Ett~- cacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus e- valuation of rituximab trim [J]. Arthritis Rheum,2010, 62(1): 222-233.
9BISSONNETFE R,LANGLEY RG, PAPP K, et al. Human- ized anti-CD2monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo controlled studies of intravenous and subcutaneous siplizum-ab [J]. Arch Dermatol Res, 2009, 301(6):429-442.
10METZ M,BERGMANN P, ZUBERBIER T, et al. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy[J].Allergy,2008,63(2):247-249.
